Posted January 2017
Biologic medications, such as TNF inhibitors (TNFi) and IL-17 inhibitors (IL-17i), are the current standard in rheumatologic treatment of moderate to severe spondyloarthritis. But what happens when patients don’t respond to this class of medications?
The following is an announcement from SAA about a third party clinical trial. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
Posted December 2016
AbbVie is giving away 45 college scholarships of $15,000 each to U.S. residents living with inflammatory diseases.
Esteemed rheumatologist and researcher, Atul Deodhar, M.D., M.R.C.P. discusses his new axial spondyloarthritis study, which concludes in supporting TNF inhibitor use in nonradiographic axial spondyloarthritis.
What you can do if you are suffering but don’t have health insurance and can’t afford to see a doctor or get treatment.
PO Box 5872
Sherman Oaks, CA 91413
(800) 777-8189 U.S. only
or (818) 892-1616